Polyunsaturated Fatty Acids: Impact on Health and Disease Status
Abstract
Over the last decades, the polyunsaturated fatty acids (PUFAs) have been largely explored not only for their nutritional value but also for the numerous biological functions and therapeutic effects. The serum and erythrocyte levels of PUFAs depend on the genetic control of metabolism as well as the dietary intake and are considered to reflect the health and disease status of an individual. Two families of PUFAs, omega-3 (n-3) and omega-6 (n-6), have gained much attention because of their involvement in the production of bioactive lipid mediators and therefore, a balanced omega-6/omega-3 ratio is crucial in maintaining the overall health of an individual. Omega-3 PUFAs, notably eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) have been shown to exert beneficial effects, possibly due to their lipid-lowering, anti-inflammatory, anti-hypertensive and cardioprotective effects, whereas omega-6 fatty acids such as arachidonic acid (ARA, 20:4n-6) exhibit the opposite properties. Even though, numerous epidemiological studies and clinical interventions have clearly established the effectiveness of omega-3 PUFAs in various pathological conditions including dyslipidemia, obesity, diabetes, cancer, cardiovascular and neurodegenerative diseases, some controversies do exist about the beneficial effects of omega-3 PUFAs and need to be clarified. Larger clinical trials with extended follow-up periods are required along with a careful dose selection, in order to confirm the clinical significance and efficacy of omega-3 PUFAs as therapeutic agents.
References
Zarate R, El Jaber-Vazdekis N, Tejera N, Perez JA, Rodriguez C. Significance of long chain polyunsaturated fatty acids in human health. Clin Transl Med. 2017; 6: 25.
Mathias RA, Fu W, Akey JM, Ainsworth HC, Torgerson DG, Ruczinski I, et al. Adaptive evolution of the FADS gene cluster within Africa. PLoS One. 2012; 7: e44926.
Stark AH, Crawford MA, Reifen R. Update on alpha-linolenic acid. Nutr Rev. 2008; 66: 326-32.
Hussein N, Ah-Sing E, Wilkinson P, Leach C, Griffin BA, Millward DJ. Long-chain conversion of [13C]linoleic acid and alpha-linolenic acid in response to marked changes in their dietary intake in men. J Lipid Res. 2005; 46: 269-80.
Benatti P, Peluso G, Nicolai R, Calvani M. Polyunsaturated fatty acids: biochemical, nutritional and epigenetic properties. J Am Coll Nutr. 2004; 23: 281-302.
Jonasdottir SH. Fatty Acid Profiles and Production in Marine Phytoplankton. Mar Drugs. 2019; 17: 151.
Peltomaa E, Johnson MD, Taipale SJ. Marine Cryptophytes Are Great Sources of EPA and DHA. Mar Drugs. 2017; 16: 3.
Moi IM, Leow ATC, Ali MSM, Rahman R, Salleh AB, Sabri S. Polyunsaturated fatty acids in marine bacteria and strategies to enhance their production. Appl Microbiol Biotechnol. 2018; 102: 5811-26.
Ghiffary MR, Kim HU, Chang YK. Metabolic Engineering Strategies for the Enhanced Microalgal Production of Long- Chain Polyunsaturated Fatty Acids (LC-PUFAs). Biotechnol J. 2019; 14: e1900043.
Wang Y, Botolin D, Xu J, Christian B, Mitchell E, Jayaprakasam B, et al. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J Lipid Res. 2006; 47: 2028-41.
Burke PA, Ling PR, Forse RA, Lewis DW, Jenkins R, Bistrian BR. Sites of conditional essential fatty acid deficiency in end stage liver disease. JPEN J Parenter Enteral Nutr. 2001; 25: 188-93.
Moore SA, Hurt E, Yoder E, Sprecher H, Spector AA. Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid. J Lipid Res. 1995; 36: 2433-43.
Su HM, Moser AB, Moser HW, Watkins PA. Peroxisomal straight-chain Acyl-CoA oxidase and D-bifunctional protein are essential for the retroconversion step in docosahexaenoic acid synthesis. J Biol Chem. 2001; 276: 38115-20.
Sprecher H, Chen Q. Polyunsaturated fatty acid biosynthesis: a microsomal-peroxisomal process. Prostaglandins, Leukotrienes and Essential Fatty Acids. 1999; 60: 317-21.
Sprecher H. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2000; 1486: 219-31.
Saini RK, Keum YS. Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance - A review. Life Sci. 2018; 203: 255-67.
Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res. 2008; 47: 147-55.
Simopoulos AP. Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet. World Rev Nutr Diet. 2011; 102: 10-21.
Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev. 2010; 68: 280-9.
Weylandt KH, Serini S, Chen YQ, Su HM, Lim K, Cittadini A, et al. Omega-3 Polyunsaturated Fatty Acids: The Way Forward in Times of Mixed Evidence. Biomed Res Int. 2015; 2015: 143109.
Amjad KW, Chun-Mei H, Khan N, Iqbal A, Lyu SW, Shah F. Bioengineered Plants Can Be a Useful Source of Omega-3 Fatty Acids. Biomed Res Int. 2017; 2017: 7348919.
Shahidi F, Ambigaipalan P. Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits. Annu Rev Food Sci Technol. 2018; 9: 345-81.
Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). 2001 May 16. Report No. 0098-7484 (Print) 0098-7484 (Linking) Contract No. 19.
Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112: 3066-72.
Guo XF, Li X, Shi M, Li D. n-3 Polyunsaturated Fatty Acids and Metabolic Syndrome Risk: A Meta-Analysis. Nutrients. 2017; 9: 703.
Lorente-Cebrian S, Costa AG, Navas-Carretero S, Zabala M, Martinez JA, Moreno-Aliaga MJ. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. J Physiol Biochem. 2013; 69: 633-51.
Carpentier YA, Portois L, Malaisse WJ. n-3 fatty acids and the metabolic syndrome. Am J Clin Nutr. 2006; 83: 1499S-504S.
Chen C, Yu X, Shao S. Effects of Omega-3 Fatty Acid Supplementation on Glucose Control and Lipid Levels in
Type 2 Diabetes: A Meta-Analysis. PLoS One. 2015; 10: e0139565.
Vanhala M, Saltevo J, Soininen P, Kautiainen H, Kangas AJ, Ala-Korpela M, et al. Serum omega-6 polyunsaturated fatty acids and the metabolic syndrome: a longitudinal population-based cohort study. Am J Epidemiol. 2012; 176: 253-60.
Brown TJ, Brainard J, Song F, Wang X, Abdelhamid A, Hooper L, et al. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019; 366: l4697.
Akinkuolie AO, Ngwa JS, Meigs JB, Djousse L. Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta- analysis of randomized controlled trials. Clin Nutr. 2011; 30: 702-7.
Rossi AS, Lombardo YB, Lacorte JM, Chicco AG, Rouault C, Slama G, et al. Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin- resistant rats. Am J Physiol Regul Integr Comp Physiol. 2005; 289: R486-R94.
Kondo K, Morino K, Nishio Y, Kondo M, Fuke T, Ugi S, et al. Effects of a fish-based diet on the serum adiponectin concentration in young, non-obese, healthy Japanese subjects. J Atheroscler Thromb. 2010; 17: 628-37.
Du S, Jin J, Fang W, Su Q. Does Fish Oil Have an Anti-Obesity Effect in Overweight/Obese Adults? A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2015; 10: e0142652.
Howe P, Buckley J. Metabolic health benefits of long-chain omega-3 polyunsaturated fatty acids. Mil Med. 2014; 179: 138-43.
Mortality GBD, Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause- specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Elsevier; 2016 Oct 8. Report No. 1474-547X (Electronic) 0140-6736 (Linking) Contract No. 10053.
Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ. 2013; 346: e8707.
Bird JK, Calder PC, Eggersdorfer M. The Role of n-3 Long Chain Polyunsaturated Fatty Acids in Cardiovascular Disease Prevention, and Interactions with Statins. Nutrients. 2018; 10: 775.
Goodfellow J, Bellamy MF, Ramsey MW, Jones CJH, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. Journal of the American College of Cardiology. 2000; 35: 265-70.
Hu Y, Hu FB, Manson JE. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. J Am Heart Assoc. 2019; 8: e013543.
Sethi A, Bajaj A, Khosla S, Arora RR. Statin Use Mitigate the Benefit of Omega-3 Fatty Acids Supplementation-A Meta-Regression of Randomized Trials. Am J Ther. 2016; 23: e737-48.
Zhu Bq, Sievers RE, Sun Yp, Morse-Fisher N, Parmley WW, Wolfe CL. Is the reduction of myocardial infarct size by dietary fish oil the result of altered platelet function? American Heart Journal. 1994; 127: 744-55.
Yang BC, Saldeen TGP, Bryant JL, Nichols WW, Mehta JL. Long-term dietary fish oil supplementation protects against ischemia-reperfusion-induced myocardial dysfunction in isolated rat hearts. American Heart Journal. 1993; 126: 1287-92.
Ogita H, Node K, Asanuma H, Sanada S, Takashima S, Minamino T, et al. Eicosapentaenoic acid reduces myocardial injury induced by ischemia and reperfusion in rabbit hearts. J Cardiovasc Pharmacol. 2003; 41: 964-9.
Xiao YF, Sigg DC, Ujhelyi MR, Wilhelm JJ, Richardson ES, Iaizzo PA. Pericardial delivery of omega-3 fatty acid: a novel approach to reducing myocardial infarct sizes and arrhythmias. Am J Physiol Heart Circ Physiol. 2008; 294: H2212-8.
Oomen CM, Feskens EJ, Rasanen L, Fidanza F, Nissinen AM, Menotti A, et al. Fish consumption and coronary heart disease mortality in Finland, Italy, and The Netherlands. Am J Epidemiol. 2000; 151: 999-1006.
Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. The American Journal of Medicine. 2002; 112: 298-304.
Harris WS, Poston WC, Haddock CK. Tissue n-3 and n-6 fatty acids and risk for coronary heart
disease events. Atherosclerosis. 2007; 193: 1-10.
Choo J, Ueshima H, Curb JD, Shin C, Evans RW, El-Saed A, et al. Serum n-6 fatty acids and lipoprotein subclasses in middle-aged men: the population-based cross-sectional ERA-JUMP study. Am J Clin Nutr. 2010; 91: 1195-203.
Tummala R, Ghosh RK, Jain V, Devanabanda AR, Bandyopadhyay D, Deedwania P, et al. Fish
Oil and Cardiometabolic Diseases: Recent Updates and Controversies. The American Journal of Medicine. 2019; 132: 1153-9.
Bowman L, Mafham M, Stevens W, Haynes R, Aung T, Chen F, et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. Am Heart J. 2018; 198: 135-44.
Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019; 380: 23-32.
Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77917 Individuals. JAMA Cardiol. 2018; 3: 225-34.
Abdelhamid A, Martin N, Bridges C, Song F, Deane KHO, Hooper L. Polyunsaturated fat intake for prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2016.
Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015; 1851: 469-84.
Mantzioris E, Cleland LG, Gibson RA, Neumann MA, Demasi M, James MJ. Biochemical effects of a diet containing foods enriched with n-3 fatty acids. Am J Clin Nutr. 2000; 72: 42-8.
Fritsche KL. The science of fatty acids and inflammation. Adv Nutr. 2015; 6: 293S-301S.
Endres S, Meydani SN, Ghorbani R, Schindler R, Dinarello CA. Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation. Journal of Leukocyte Biology. 1993; 54: 599-603.
Miles EA, Calder PC. Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Br J Nutr. 2012; 107: S171-84.
Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab. 2006; 91: 439-46.
Sabour H, Larijani B, Vafa MR, Hadian MR, Heshmat R, Meybodi HA, et al. The effects of n-3 fatty acids on inflammatory cytokines in osteoporotic spinal cord injured patients: A randomized clinical trial. J Res Med Sci. 2012; 17: 322-7.
Su H, Liu R, Chang M, Huang J, Jin Q, Wang X. Effect of dietary alpha-linolenic acid on blood inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Eur J Nutr. 2018; 57: 877-91.
Johnson GH, Fritsche K. Effect of dietary linoleic acid on markers of inflammation in healthy
persons: a systematic review of randomized controlled trials. J Acad Nutr Diet. 2012; 112: 1029-41.
Pashkow FJ. Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention? Int J Inflam. 2011; 2011: 514623.
Mazereeuw G, Lanctot KL, Chau SA, Swardfager W, Herrmann N. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging. 2012; 33: e17-29.
Nowak JZ. Oxidative stress, polyunsaturated fatty acids-derived oxidation products and bis retinoids as potential inducers of CNS diseases: focus on age-related macular degeneration. Pharmacol Rep. 2013; 65: 288-304.
Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol. 2005; 58: 730-5.
Azizi-Soleiman F, Jazayeri S, Eghtesadi S, Rajab A, Heidari I, Vafa MR, et al. Effects of pure eicosapentaenoic and docosahexaenoic acids on oxidative stress, inflammation and body fat mass in patients with type 2 diabetes. International journal of preventive medicine. 2013; 4: 922-8.
Mazereeuw G, Herrmann N, Andreazza AC, Scola G, Ma DWL, Oh PI, et al. Oxidative stress predicts depressive symptom changes with omega-3 fatty acid treatment in coronary artery disease patients. Brain Behav Immun. 2017; 60: 136-41.
Abdukeyum GG, Owen AJ, Larkin TA, McLennan PL. Up-Regulation of Mitochondrial Antioxidant Superoxide Dismutase Underpins Persistent Cardiac Nutritional-Preconditioning by Long Chain n-3 Polyunsaturated Fatty Acids in the Rat. Journal of clinical medicine. 2016; 5: 32.
Mazereeuw G, Herrmann N, Oh PI, Ma DW, Wang CT, Kiss A, et al. Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Psychopharmacol. 2016; 36: 436-44.
Okereke OI, Reynolds CF, 3rd, Mischoulon D, Chang G, Cook NR, Copeland T, et al. The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression. Contemp Clin Trials. 2018; 68: 133-45.
Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement. 2015; 11: 718-26.
Zanoaga O, Jurj A, Raduly L, Cojocneanu-Petric R, Fuentes-Mattei E, Wu O, et al. Implications of dietary omega-3 and omega-6 polyunsaturated fatty acids in breast cancer. Exp Ther Med. 2018; 15: 1167-76.
Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reproduction Nutrition Development. 2004; 44: 273-82.
Simopoulos AP. The omega-6/omega-3 fatty acid ratio: health implications. Oléagineux, Corps gras, Lipides. 2010; 17: 267-75.
Fradet V, Cheng I, Casey G, Witte JS. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res. 2009; 15: 2559-66.
Courtney ED, Matthews S, Finlayson C, Di Pierro D, Belluzzi A, Roda E, et al. Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas. Int J Colorectal Dis. 2007; 22: 765-76.
Wolk A, Larsson SC, Johansson JE, Ekman P. Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA. 2006; 296: 1371-6.
Zheng JS, Hu XJ, Zhao YM, Yang J, Li D. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ. 2013; 346: f3706.
Zuijdgeest-van Leeuwen SD, van der Heijden MS, Rietveld T, van den Berg JW, Tilanus HW, Burgers JA, et al. Fatty acid composition of plasma lipids in patients with pancreatic, lung and oesophageal cancer in comparison with healthy subjects. Clin Nutr. 2002; 21: 225-30.
Miryaghoubzadeh J, Darabi M, Madaen K, Shaaker M, Mehdizadeh A, Hajihosseini R. Tissue fatty acid composition in human urothelial carcinoma. Br J Biomed Sci 2013; 70: 1-5.
Jurczyszyn A, Czepiel J, Gdula-Argasinska J, Pasko P, Czapkiewicz A, Librowski T, et al. Plasma
fatty acid profile in multiple myeloma patients. Leuk Res. 2015; 39: 400-5.
Zhang B, Wei G, Li R, Wang Y, Yu J, Wang R, et al. n-3 fatty acid-based parenteral nutrition
improves postoperative recovery for cirrhotic patients with liver cancer: A randomized
controlled clinical trial. Clin Nutr. 2017; 36: 1239-44.
Eltweri AM, Thomas AL, Chung WY, Morgan B, Thompson J, Dennison AR, et al. The Effect of Supplementary Omegaven(R) on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial. Anticancer Res. 2019; 39: 853-61.
Hanson S, Thorpe G, Winstanley L, Abdelhamid AS, Hooper L, group P. Omega-3, omega-6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta- analysis of randomised trials. Br J Cancer. 2020; 122: 1260-70.
Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids. 2000; 35: 1305-12.
Innis SM. Dietary omega 3 fatty acids and the developing brain. Brain Res. 2008; 1237: 35- 43.
Cederholm T, Salem N, Palmblad J. omega-3 fatty acids in the prevention of cognitive decline in humans. Adv Nutr. 2013; 4: 672-6.
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014; 88: 640-51.
Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001; 81: 741-66.
Zhang X, Fu Z, Meng L, He M, Zhang Z. The Early Events That Initiate beta-Amyloid Aggregation in Alzheimer's Disease. Front Aging Neurosci. 2018; 10: 359.
Hjorth E, Zhu M, Toro VC, Vedin I, Palmblad J, Cederholm T, et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-beta42 by human microglia and decrease inflammatory markers. J Alzheimers Dis. 2013; 35: 697-713.
Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, et al. A diet enriched with the omega- 3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci. 2005; 25: 3032-40.
Avallone R, Vitale G, Bertolotti M. Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials. Int J Mol Sci. 2019; 20: 4256.
Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, et al. Low serum cholesteryl ester- docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr. 2003; 89: 483-9.
Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease:
OmegAD study: a randomized double-blind trial. Arch Neurol. 2006; 63: 1402-8.
Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A. Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev. 2016; 4: CD009002.
Esposito G, Giovacchini G, Liow JS, Bhattacharjee AK, Greenstein D, Schapiro M, et al. Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. J Nucl Med. 2008; 49: 1414-21.
Rapoport SI. Arachidonic acid and the brain. J Nutr. 2008; 138: 2515-20.
Thomas MH, Paris C, Magnien M, Colin J, Pelleieux S, Coste F, et al. Dietary arachidonic acid increases deleterious effects of amyloid-beta oligomers on learning abilities and expression of AMPA receptors: putative role of the ACSL4-cPLA2 balance. Alzheimers Res Ther. 2017; 9: 69.
Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem. 2007; 101: 577-99.
Samieri C, Feart C, Letenneur L, Dartigues JF, Peres K, Auriacombe S, et al. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr. 2008; 88: 714-21.
Goetz CG. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011; 1: a008862.
Bousquet M, Saint-Pierre M, Julien C, Salem N, Cicchetti F, Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J. 2008; 22: 1213-25.
Coulombe K, Saint-Pierre M, Cisbani G, St-Amour I, Gibrat C, Giguère-Rancourt A, et al. Partial neurorescue effects of DHA following a 6-OHDA lesion of the mouse dopaminergic system. The Journal of Nutritional Biochemistry. 2016; 30: 133-42.
da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. 2008; 111: 351-9.
Pomponi M, Loria G, Salvati S, Di Biase A, Conte G, Villella C, et al. DHA effects in Parkinson disease depression. Basal Ganglia. 2014; 4: 61-6.
Taghizadeh M, Tamtaji OR, Dadgostar E, Daneshvar Kakhaki R, Bahmani F, Abolhassani J, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: A randomized, double-blind, placebo- controlled trial. Neurochem Int. 2017; 108: 183-9.
Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, Tsuboi Y, et al. Dietary fat intake and risk of Parkinson's disease: a case-control study in Japan. J Neurol Sci. 2010; 288: 117-22.
Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport. 2002; 13: 123-6.
Hatami A, Zhu C, Relano-Gines A, Elias C, Galstyan A, Jun M, et al. Deuterium-reinforced linoleic acid lowers lipid peroxidation and mitigates cognitive impairment in the Q140 knock in mouse model of Huntington's disease. FEBS J. 2018; 285: 3002-12.
Fitzgerald KC, O'Reilly EJ, Falcone GJ, McCullough ML, Park Y, Kolonel LN, et al. Dietary omega-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol. 2014; 71: 1102-10.
Schlanger S, Shinitzky M, Yam D. Diet enriched with omega-3 fatty acids alleviates convulsion symptoms in epilepsy patients. Epilepsia. 2002; 43: 103-4.
